Research progress of blood-based DNA methylation in diagnosis of liver cancer

LI Fangfang; TAO Ziwei; SHEN Yongli; WENG Yali

doi:10.7619/jcmp.20210641

Journal of Clinical Medicine in Practice > 2021 > 25(9): 117-122. > DOI: 10.7619/jcmp.20210641

LI Fangfang, TAO Ziwei, SHEN Yongli, WENG Yali. Research progress of blood-based DNA methylation in diagnosis of liver cancer[J]. Journal of Clinical Medicine in Practice, 2021, 25(9): 117-122. DOI: 10.7619/jcmp.20210641

Citation:

PDF (613 KB)

Research progress of blood-based DNA methylation in diagnosis of liver cancer

Department of Infectious Diseases, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029

More Information

Received Date: February 06, 2021
Available Online: May 20, 2021
Published Date: May 14, 2021

Graphical Abstract

Abstract

Abstract

Liver cancer is one of the most lethal cancer types world-wide with low early diagnosis, and the patient is usually in advanced stage when the disease is diagnosed. Early diagnosis is an important means to reduce the mortality of patients with liver cancer, but there is no reliable hematological molecular marker for the diagnosis of liver cancer. Circulating free DNA (cfDNA) methylation detection is a potential non-invasive method for tumor diagnosis. Combined with the recent studies on circulating free DNA methylation in the diagnosis of liver cancer, this paper mainly reviewed the research progress of single DNA methylation markers in blood, the combination of multiple DNA methylation markers, and the combination of DNA methylation markers with alpha-fetoprotein (AFP) in the diagnosis of liver cancer.
- liver cancer,
- DNA methylation,
- noninvasive diagnosis,
- blood biomarker

FullText(HTML)

References (57)

References

[1]	VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15): 1450-1462. doi: 10.1056/NEJMra1713263
[2]	MCGLYNN K A, PETRICK J L, LONDON W T. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability[J]. Clin Liver Dis, 2015, 19(2): 223-238. doi: 10.1016/j.cld.2015.01.001
[3]	European Association for the Study of the Liver. Electronic address: easloffice@easloffice. eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. doi: 10.1016/j.jhep.2018.03.019
[4]	LU L C, HSU C H, HSU C, et al. Tumor heterogeneity in hepatocellular carcinoma: facing the challenges[J]. Liver Cancer, 2016, 5(2): 128-138. doi: 10.1159/000367754
[5]	中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. doi: 10.3969/j.issn.1001-5256.2020.02.007
[6]	HE G X, CHEN Y H, ZHU C P, et al. Application of plasma circulating cell-free DNA detection to the molecular diagnosis of hepatocellular carcinoma[J]. Am J Transl Res, 2019, 11(3): 1428-1445. http://www.ncbi.nlm.nih.gov/pubmed/30972172
[7]	MA K, LIU J Y, WANG Y J, et al. Relationship between plasma cell-free DNA (cfDNA) and prognosis of TACE for primary hepatocellular carcinoma[J]. J Gastrointest Oncol, 2020, 11(6): 1350-1363. doi: 10.21037/jgo-20-509
[8]	ALUNNI-FABBRONI M, RÖNSCH K, HUBER T, et al. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial[J]. J Transl Med, 2019, 17(1): 328. doi: 10.1186/s12967-019-2079-9
[9]	LIAO W J, YANG H Y, XU H F, et al. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing[J]. Oncotarget, 2016, 7(26): 40481-40490. doi: 10.18632/oncotarget.9629
[10]	CHENG J M, WEI D K, JI Y, et al. Integrative analysis of DNA methylation and gene expression reveals hepatocellular carcinoma-specific diagnostic biomarkers[J]. Genome Med, 2018, 10(1): 42. doi: 10.1186/s13073-018-0548-z
[11]	VILLANUEVA A, PORTELA A, SAYOLS S, et al. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma[J]. Hepatology, 2015, 61(6): 1945-1956. doi: 10.1002/hep.27732
[12]	SUN K, JIANG P Y, CHAN K C, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments[J]. Proc Natl Acad Sci USA, 2015, 112(40): E5503-E5512. doi: 10.1073/pnas.1508736112
[13]	VOGELSTEIN B, PAPADOPOULOS N, VELCULESCU V E, et al. Cancer genome landscapes[J]. Science, 2013, 339(6127): 1546-1558. doi: 10.1126/science.1235122
[14]	SCHULZE K, NAULT J C, VILLANUEVA A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing[J]. J Hepatol, 2016, 65(5): 1031-1042. doi: 10.1016/j.jhep.2016.05.035
[15]	MONTAVON C, GLOSS B S, WARTON K, et al. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer[J]. Gynecol Oncol, 2012, 124(3): 582-588. doi: 10.1016/j.ygyno.2011.11.026
[16]	ROBERTSON K D. DNA methylation and human disease[J]. Nat Rev Genet, 2005, 6(8): 597-610. http://www.mendeley.com/catalog/dna-methylation-human-disease-9/
[17]	WU X, LI J, GASSA A, et al. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma[J]. Int J Biol Sci, 2020, 16(9): 1551-1562. doi: 10.7150/ijbs.44024
[18]	ZHANG C, LI J Y, HUANG T, et al. Meta-analysis of DNA methylation biomarkers in hepatocellular carcinoma[J]. Oncotarget, 2016, 7(49): 81255-81267. doi: 10.18632/oncotarget.13221
[19]	YANG X F, GAO L, ZHANG S H. Comparative Pan-cancer DNA methylation analysis reveals cancer common and specific patterns[J]. Brief Bioinform, 2017, 18(5): 761-773.
[20]	LI L, CHOI J Y, LEE K M, et al. DNA methylation in peripheral blood: a potential biomarker for cancer molecular epidemiology[J]. J Epidemiol, 2012, 22(5): 384-394. doi: 10.2188/jea.JE20120003
[21]	SHEN S Y, SINGHANIA R, FEHRINGER G, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes[J]. Nature, 2018, 563(7732): 579-583. doi: 10.1038/s41586-018-0703-0
[22]	CHURCH T R, WANDELL M, LOFTON-DAY C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer[J]. Gut, 2014, 63(2): 317-325. doi: 10.1136/gutjnl-2012-304149
[23]	LIGGETT T E, MELNIKOV A, YI Q L, et al. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors[J]. Gynecol Oncol, 2011, 120(1): 113-120. doi: 10.1016/j.ygyno.2010.09.019
[24]	MAH W C, LEE C G. DNA methylation: potential biomarker in Hepatocellular Carcinoma[J]. Biomark Res, 2014, 2(1): 5. doi: 10.1186/2050-7771-2-5
[25]	WANG W W, CHEN G Y, WANG B, et al. Long non-coding RNA BZRAP1-AS1 silencing suppresses tumor angiogenesis in hepatocellular carcinoma by mediating THBS1 methylation[J]. J Transl Med, 2019, 17(1): 421. doi: 10.1186/s12967-019-02145-6
[26]	LIU A, WU Q, PENG D, et al. A novel strategy for the diagnosis, prognosis, treatment, and chemoresistance of hepatocellular carcinoma: DNA methylation[J]. Med Res Rev, 2020, 40(5): 1973-2018. doi: 10.1002/med.21696
[27]	CHEN G, FAN X, LI Y, et al. Promoter aberrant methylation status of ADRA1A is associated with hepatocellular carcinoma[J]. Epigenetics, 2020, 15(6/7): 684-701. doi: 10.1080/15592294.2019.1709267
[28]	UMETSU S, MIZUKAMI H, SAITO T, et al. Diabetes, an independent poor prognostic factor of non-B non-C hepatocellular carcinoma, correlates with dihydropyrimidinase-like 3 promoter methylation[J]. Sci Rep, 2020, 10(1): 1156. doi: 10.1038/s41598-020-57883-1
[29]	WONG I H, LO Y M, ZHANG J, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients[J]. Cancer Res, 1999, 59(1): 71-73.
[30]	ZHAO Z H, FAN Y C, YANG Y, et al. Association between Ras association domain family 1A promoter methylation and hepatocellular carcinoma: a meta-analysis[J]. World J Gastroenterol, 2013, 19(41): 7189-7196. doi: 10.3748/wjg.v19.i41.7189
[31]	LI B L, HUANG H, HUANG R H, et al. SEPT9 gene methylation as a noninvasive marker for hepatocellular carcinoma[J]. Dis Markers, 2020, 2020: 6289063. http://www.researchgate.net/publication/346512858_SEPT9_Gene_Methylation_as_a_Noninvasive_Marker_for_Hepatocellular_Carcinoma
[32]	TIAN M P, ZHAO B H, ZHANG J, et al. Association of environmental benzo[a]Pyrene exposure and DNA methylation alterations in hepatocellular carcinoma: a Chinese case-control study[J]. Sci Total Environ, 2016, 541: 1243-1252. doi: 10.1016/j.scitotenv.2015.10.003
[33]	WU H C, YANG H I, WANG Q, et al. Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population[J]. Carcinogenesis, 2017, 38(10): 1021-1028. doi: 10.1093/carcin/bgx078
[34]	IYER P, ZEKRI A R, HUNG C W, et al. Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients[J]. Exp Mol Pathol, 2010, 88(1): 107-111. doi: 10.1016/j.yexmp.2009.09.012
[35]	XU F, ZHANG L L, XU Y X, et al. Hypermethylation of SCAND3 and Myo1g gene are potential diagnostic biomarkers for hepatocellular carcinoma[J]. Cancers, 2020, 12(8): 2332. doi: 10.3390/cancers12082332
[36]	LIU X Y, FAN Y C, GAO S, et al. Methylation of SOX1 and VIM promoters in serum as potential biomarkers for hepatocellular carcinoma[J]. Neoplasma, 2017, 64(5): 745-753. doi: 10.4149/neo_2017_513
[37]	WEI L, HUANG Y, ZHAO R C, et al. Detection of promoter methylation status of suppressor of cytokine signaling 3(SOCS3) in tissue and plasma from Chinese patients with different hepatic diseases[J]. Clin Exp Med, 2018, 18(1): 79-87. doi: 10.1007/s10238-017-0473-2
[38]	XIE G F, XU Y X, XU F, et al. Plasma SGIP1 methylation in diagnosis and prognosis prediction in hepatocellular carcinoma[J]. Neoplasma, 2021, 68(1): 62-70. doi: 10.4149/neo_2020_200623N657
[39]	FEINBERG A P, TYCKO B. The history of cancer epigenetics[J]. Nat Rev Cancer, 2004, 4(2): 143-153. doi: 10.1038/nrc1279
[40]	VAN TONGELEN A, LORIOT A, DE SMET C. Oncogenic roles of DNA hypomethylation through the activation of cancer-germline genes[J]. Cancer Lett, 2017, 396: 130-137. doi: 10.1016/j.canlet.2017.03.029
[41]	RAMZY I I, OMRAN D A, HAMAD O, et al. Evaluation of serum LINE-1 hypomethylation as a prognostic marker for hepatocellular carcinoma[J]. Arab J Gastroenterol, 2011, 12(3): 139-142. doi: 10.1016/j.ajg.2011.07.002
[42]	CHAN K C, JIANG P Y, CHAN C W, et al. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing[J]. Proc Natl Acad Sci USA, 2013, 110(47): 18761-18768. doi: 10.1073/pnas.1313995110
[43]	WEN L, LI J Y, GUO H H, et al. Genome-scale detection of hypermethylated CpG Islands in circulating cell-free DNA of hepatocellular carcinoma patients[J]. Cell Res, 2015, 25(12): 1376. doi: 10.1038/cr.2015.141
[44]	XU R H, WEI W, KRAWCZYK M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater, 2017, 16(11): 1155-1161. doi: 10.1038/nmat4997
[45]	KISIEL J B, DUKEK B A, V S R KANIPAKAM R, et al. Hepatocellular carcinoma detection by plasma methylated DNA: discovery, phase I pilot, and phase II clinical validation[J]. Hepatology, 2019, 69(3): 1180-1192. http://www.researchgate.net/publication/327344722_Hepatocellular_Carcinoma_Detection_by_Plasma_Methylated_DNA_Discovery_Phase_I_Pilot_and_Phase_II_Clinical_Validation
[46]	TIAN M M, FAN Y C, ZHAO J, et al. Hepatocellular carcinoma suppressor 1 promoter hypermethylation in serum. A diagnostic and prognostic study in hepatitis B[J]. Clin Res Hepatol Gastroenterol, 2017, 41(2): 171-180. doi: 10.1016/j.clinre.2016.10.003
[47]	DONG X Y, HOU Q, CHEN Y M, et al. Diagnostic value of the methylation of multiple gene promoters in serum in hepatitis B virus-related hepatocellular carcinoma[J]. Dis Markers, 2017, 2017: 2929381. http://pubmedcentralcanada.ca/pmcc/articles/PMC5603249/
[48]	ZHANG C, HUANG C X, SUI X B, et al. Association between gene methylation and HBV infection in hepatocellular carcinoma: a meta-analysis[J]. J Cancer, 2019, 10(25): 6457-6465. doi: 10.7150/jca.33005
[49]	XIANG L, CHEN L M, ZHAI Y J, et al. Hypermethylation of secreted frizzled related protein 2 gene promoter serves as a noninvasive biomarker for HBV-associated hepatocellular carcinoma[J]. Life Sci, 2021, 270: 119061. doi: 10.1016/j.lfs.2021.119061
[50]	ZEKRI A E L-R, NASSAR A A, EL-DIN EL-ROUBY M N, et al. Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation[J]. Asian Pac J Cancer Prev, 2014, 14(11): 6721-6726.
[51]	ELSEWIFY W A E, HASSAN E A, MEKKY M A, et al. Usefulness of circulating methylated p16 as a noninvasive molecular biomarker for hepatitis C-related hepatocellular carcinoma with normal serum alpha-fetoprotein levels[J]. Int J Gen Med, 2020, 13: 147-155. doi: 10.2147/IJGM.S249272
[52]	CHALASANI N P, RAMASUBRAMANIAN T S, BHATTACHARYA A, et al. A novel blood-based panel of methylated DNA and protein markers for detection of early-stage hepatocellular carcinoma[J]. Clin Gastroenterol Hepatol, 2020: S1542-S3565(20)31224-6. http://www.sciencedirect.com/science/article/pii/S1542356520312246
[53]	PASHA H F, MOHAMED R H, RADWAN M I. RASSF1A and SOCS1 genes methylation status as a noninvasive marker for hepatocellular carcinoma[J]. Cancer Biomark, 2019, 24(2): 241-247. doi: 10.3233/CBM-181638
[54]	ZHANG Y J, WU H C, SHEN J, et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA[J]. Clin Cancer Res, 2007, 13(8): 2378-2384. doi: 10.1158/1078-0432.CCR-06-1900
[55]	LIU M, JIANG L X, GUAN X Y. The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update[J]. Protein Cell, 2014, 5(9): 673-691. doi: 10.1007/s13238-014-0065-9
[56]	CHEN X, ZHANG J T, RUAN W M, et al. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer[J]. J Clin Invest, 2020, 130(12): 6278-6289. doi: 10.1172/JCI139597
[57]	SHIN S H, LEE K, KIM B H, et al. Bile-based detection of extrahepatic cholangiocarcinoma with quantitative DNA methylation markers and its high sensitivity[J]. J Mol Diagn, 2012, 14(3): 256-263. doi: 10.1016/j.jmoldx.2012.01.014

Cited By

Cited by

Periodical cited type(2)

1.	居冠军，施民新，樊怿辉，陈赛华，刘红利，龚海鹏，朱桂娟. 血浆循环游离DNA水平及其完整性用于肺结节良恶性的诊断研究. 实用临床医药杂志. 2023(07): 25-29 . 本站查看
2.	侯宝洲，李慧平，魏思忱，穆宗玮，李丽娟，田树英. 原发性肝细胞癌患者血清血管内皮细胞生长因子、可溶性胸苷激酶-1和T淋巴细胞亚群的临床意义. 实用临床医药杂志. 2022(07): 98-102+108 . 本站查看

Other cited types(1)

Get Citation

PDF

XML

Article views (388) PDF downloads (34) Cited by(3)

Turn off MathJax

Article Contents

Abstract

References

Research progress of blood-based DNA methylation in diagnosis of liver cancer

Abstract

References

Cited by

Periodical cited type(2)

Other cited types(1)

Catalog

Export File

Citation

Format

Content